Molecular Formula	C14H13N3O4S2
Molecular Weight	351.4
Structure
State	solid
Clearance	* 8.8 mL/min [Healthy Male Adults (Fed) oral 7.5 mg tablets] * 9.9 mL/min [Eldery Male (Fed) oral 15 mg capsules] * 5.1 mL/min [Eldery Female (Fed) oral 15 mg capsules] * 19 mL/min [Renal Failure (Fasted) oral 15 mg capsules] * 11 mL/min [Hepatic Insufficiency (Fasted) oral 15 mg capsules]
Volume of distribution	* 10 L
Route of elimination	Meloxicam is almost completely metabolized to four pharmacologically inactive metabolites. Meloxicam excretion is predominantly in the form of metabolites, and occurs to equal extents in the urine and feces. Only traces of the unchanged parent compound are excreted in the urine (0.2%) and feces (1.6%). The extent of the urinary excretion was confirmed for unlabeled multiple 7.5 mg doses: 0.5%, 6% and 13% of the dose were found in urine in the form of meloxicam, and the 5'-hydroxymethyl and 5'-carboxy metabolites, respectively.
Protein binding	99.4% bound, primarily to albumin
Half life	15-20 hours
Absorption	Absolute bioavailability = 89%
Trade names	Mobic
Description	nonsteroidal anti-inflammatory drug (NSAID); blocks cyclooxygenase-2 (COX-2) ; oxicam family; analgesics;

Toxicity	Dose	Time	Species	Model	Method	Action	Positive criterion	Reference
TRANSMEMBRANE POTENTIAL	382	24hr	rat	hepatocytes	tetramethylrhodamine ethyl ester (TMRE)	decrease	AC50 (μM)	40
UNCOUPLING								197
MEMBRANE POTENTIAL	14.47±0.00		human	qHTS-HepG2	MMP assay	decrease	IC50	163
MEMBRANE POTENTIAL			human	HepG2	MMP assay	Negative	IC50	163
MEMBRANE POTENTIAL			rat	hepatocytes	MMP assay	Negative	IC50	163
STATE 2 RESPIRATION	22.8 ± 2.8		rat	isolated rat liver mitochondria	State 2 respiration ( 96-well plate format using a phosphorescent oxygen-sensitive probe MitoXpress)	inhibit	UC50 (nmol/mg mitochondrial protein)	40
STATE 3 RESPIRATION	100 nmol/mg mitochondrial protein		rat	isolated rat liver mitochondria	State 3 respiration ( 96-well plate format using a phosphorescent oxygen-sensitive probe MitoXpress)	Negative	IC50 (nmol/mg mitochondrial protein)	40
LIPID METABOLISM	> 500	24hr	rat	hepatocytes	LipidTox, for neutral lipid accumulation, to evaluate lipid content.	accumulation	AC50 (μM)	40
GLUTATHIONE METABOLISM	316	24hr	rat	hepatocytes	glutathion depletion: cells were incubated with 50 μM monochlorobimane with 6 μg/ml Hoechst 33342		AC50 (μM)	40
ROS PRODUCTION	NR		rat	hepatocytes	use CM-H2DCFDA to monitor reactive oxygen species	Negative	AC50 (μM)	40
CYTOCHROME C RELEASE	245	24hr	rat	hepatocytes	cytochrome c release (anti-cytochrome c antibody )	induce	AC50 (μM)	40
ER STRESS-INDUCED	153	24hr	rat	hepatocytes	DNA damage 153 induction (GADD153 antibodies) for ER-stress induced apoptosis	induce	AC50 (μM)	40

Pictogram	Signal	Statements	Precautionary Statement Codes
	Danger	H372: Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure]	P260, P264, P270, P314, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)

Acute coronary syndrome

Arthritis

Arthropathy

Cerebrovascular accident

Gastrointestinal disorder

Inflammation

Juvenile idiopathic arthritis

Myocardial infarction

Pain

Rheumatoid arthritis

Abdominal pain

Abdominal pain upper

Accident at home

Anaemia

Angiopathy

Arthralgia

Arthritis

Asthenia

Back pain

Blood urea increased

Bronchitis

Bursitis

Carpal tunnel syndrome

Cataract

Connective tissue disorder

Constipation

Cough

Creatinine renal clearance decreased

Dehydration

Dermatitis

Diarrhoea

Dizziness

Dry mouth

Dyspepsia

Dyspnoea

Ear disorder

Eructation

Eye disorder

Fatigue

Flatulence

Gastritis

Gastrointestinal disorder

Gastrointestinal haemorrhage

Gastrointestinal pain

Gastrooesophageal reflux disease

Gravitational oedema

Haematuria

Headache

Hepatic function abnormal

Hepatobiliary disease

Hyperhidrosis

Hypersensitivity

Hypertension

Immune system disorder

Increased appetite

Infection

Infestation

Influenza

Influenza like illness

Insomnia

Malnutrition

Mediastinal disorder

Melaena

Mental disorder

Mouth ulceration

Muscle spasms

Musculoskeletal discomfort

Myalgia

Nasopharyngitis

Nausea

Nervous system disorder

Oedema

Oedema peripheral

Pain

Pain in extremity

Pharyngitis

Pleuritic pain

Pollakiuria

Pruritus

Purpura

Rash

Rash erythematous

Red blood cell abnormality

Rheumatoid arthritis

Rhinitis

Sinusitis

Skin disorder

Somnolence

Stomatitis

Tinnitus

Upper respiratory tract infection

Urethral disorder

Urinary tract disorder

Urinary tract infection

Vascular purpura

Vertigo

Visual impairment

Vomiting

(3Z)-2-methyl-3-[[(5-methyl-1,3-thiazol-2-yl)amino]-oxidanyl-methylidene]-1,1-bis(oxidanylidene)-1$l^{6},2-benzothiazin-4-one	(3Z)-3-[hydroxy-[(5-methyl-2-thiazolyl)amino]methylidene]-2-methyl-1,1-dioxo-1$l^{6},2-benzothiazin-4-one	(E)-3-(hydroxy((5-methylthiazol-2-yl)amino)methylene)-2-methyl-2,3-dihydro-4H-benzo[e][1,2]thiazin-4-one 1,1-dioxide
1027136-06-6	125M387	133687-22-6
2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-, 1,1-dioxide	2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methylthiazolyl)-, 1,1-dioxide	3-{hydroxy[(5-methyl-1,3-thiazol-2-yl)amino]methylidene}-2-methyl-2,3-dihydro-4H-1,2-benzothiazin-4-one 1,1-dioxide
4-Hydroxy-1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[e][1,2]thiazine-3-carboxylic acid (5-methyl-thiazol-2-yl)-amide	4-Hydroxy-2-methyl-1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[e][1,2]thiazine-3-carboxylic acid (5-methyl-thiazol-2-yl)-amide	4-Hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazin-3-crboxamide 1,1-dioxide
4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide	4-Hydroxy-2-methyl-N-(5-methyl-2-thiazoyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide	4-Hydroxy-2-methyl-N-(5-methylthiazol-2-yl)-2H-benzo[e][1,2]thiazine-3-carboxamide 1,1-dioxide
4-hydroxy-2-mehtyl-N-(5-mehtyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide	4-hydroxy-2-methyl-N-(5-methy-2-thiazolyl)-2H-1,2-benzothiazine-3-caboxamide-1,1-dioxide	4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1$l^{6},2-benzothiazine-3-carboxamide
4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1?^{6},2-benzothiazine-3-carboxamide	4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-2H-1$l^{6},2-benzothiazine-3-carboxamide	4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-2H-1lambda6,2-benzothiazine-3-carboxamide
4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide	4-hydroxy-2-methyl-N-(5-methyl-2-thiazole)-2H-1,2-benzothiazine-3 -carboxamide 1,1-dioxide	4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide
71125-38-7	A837087	AB0007297
AB00383033-17	AB00383033-18	AB00383033_20
AB1009494	AC-1325	AK-77454
AKOS000279442	AKOS026749959	ALBB-027268
AN-668/13244001	ANW-57553	BBL029076
BB_SC-04648	BCP11928	BDBM50056998
BG0248	BIDD:GT0726	BSPBio_002257
C-20653	C08169	C14H13N3O4S2
CAS-71125-38-7	CC-30198	CCG-39098
CCRIS 9139	CHEBI:6741	CHEMBL1741042
CHEMBL599	CPD000718800	CS-2247
CTK6C3599	CTK6C3600	Coxflam
Coxicam	D00969	DB-055490
DB00814	DSSTox_CID_803	DSSTox_GSID_20803
DSSTox_RID_75796	DTXSID1020803	EN300-52507
ETI-511	F2173-0387	FT-0082769
FT-0628193	GTPL7220	HMS1922D19
HMS2089B18	HMS2096I19	HMS2234P07
HMS2236C09	HMS3259H06	HMS3372C13
HMS3372P18	HMS3655K06	HMS3713I19
HMS3744K09	HSCI1_000045	HSDB 7741
HY-B0261	J10218	KBio2_002113
KBio2_004681	KBio2_007249	KBio3_001477
KBioGR_001234	KBioSS_002113	KS-00000JN4
KS-1084	LS-40538	Lopac0_000766
M1959	MCULE-4138373089	MFCD00868752
MLS000028587	MLS001304725	MLS001306413
MLS006011422	MXM	Melfax
Melonex	Meloxicam (JAN/USAN/INN)	Meloxicam (Mobic)
Meloxicam 1.0 mg/ml in Dimethyl Sulfoxide	Meloxicam [USAN:BAN:INN]	Meloxicam [USAN:USP:INN:BAN]
Meloxicam(Mobic)	Meloxicam, 99-101%	Meloxicam,(S)
Meloxicamum	Meloxicamum [Latin]	Meloxivet
Metacam	Mobec	Mobic
Mobic (TN)	Mobicox	Movalis
Movatec	N-1539	NC00698
NCGC00018248-01	NCGC00018248-02	NCGC00018248-03
NCGC00018248-04	NCGC00018248-05	NCGC00018248-06
NCGC00018248-07	NCGC00018248-08	NCGC00022924-03
NCGC00022924-04	NCGC00256316-01	NCGC00259238-01
NCGC00263878-02	Opera_ID_2	Parocin
Q414028	R3928	RTR-031220
Revmoksikam	SAM002589991	SC-12165
SCHEMBL33369	SCHEMBL3576	SCHEMBL713100
SMP2_000133	SMR000058994	SMR000718800
SPBio_000902	SPECTRUM1504150	SR-01000003132-10
ST24023559	STK620505	SW219562-1
Spectrum2_000941	Spectrum3_000649	Spectrum4_000787
Spectrum5_001813	Spectrum_001633	Tenaron
Tox21_111734	Tox21_111734_1	Tox21_113192
Tox21_201689	Tox21_302756	UH-AC 62XX
UHAC-62XX	UNII-VG2QF83CGL	VG2QF83CGL
Vivlodex	Z1695493323	ZINC103620661
ZINC13129998	ZRVUJXDFFKFLMG-UHFFFAOYSA-N	ZX-AN025777
meloxicam	miloxicam	s1734

DrugBank Name	Meloxicam
DrugBank	DB00814
CAS Number	133687-22-6, 71125-38-7
PubChem Compound	54677470
KEGG Compound ID	C08169
KEGG Drug	D00969
PubChem.Substance	46506624
ChEBI	6741
PharmGKB	PA450353
ChemSpider	10442740
BindingDB	50056998.0
TTD	DAP000971
Wikipedia	Meloxicam
HET	MXM
DPD	11764